Treasury officials say the near-$1 trillion General Account (TGA) could be used to back larger long‑term bond buybacks, potentially influencing yields; the plan would rely on discretionary cash and selling short-term bills, though specifics and market impact remain uncertain amid skepticism about the operation’s effectiveness.
Australia’s Therapeutic Goods Administration warns GLP-1 receptor agonists used for diabetes and obesity (semaglutide Ozempic/Wegovy, tirzepatide Mounjaro, dulaglutide Trulicity, liraglutide Saxenda) may cause a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION), which can lead to permanent vision loss. Thirty-six cases have been reported in Australia; the warning follows a 2024 JAMA Ophthalmology study that found higher NAION risk with semaglutide. The TGA conducted an independent assessment and consulted experts. Optometry Australia says don’t panic, but seek urgent care if vision changes; risk factors include diabetes, sleep apnea, hypertension, and a crowded optic disc, with about 70% of NAION cases not recovering vision. WHO has endorsed GLP-1–style drugs for obesity; regular eye tests are advised and patients should inform eye doctors of their treatment. Do not stop medication without consulting a prescriber; EMA has noted NAION as a very rare side effect (up to 1 in 10,000).
The resolution of the debt ceiling has led to a significant rebuild of the Treasury General Account (TGA), potentially draining $400–$500 billion from market liquidity and impacting margin availability and stock prices. Market participants should monitor reserve balances closely as these shifts could have negative effects.